Tecentriq Approval History
FDA Approved: Yes (First approved May 18, 2016)
Brand name: Tecentriq
Generic name: atezolizumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Bladder Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Small Cell Lung Cancer
Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of advanced urothelial carcinoma; the treatment of metastatic non-small cell lung cancer (NSCLC); extensive-stage small cell lung cancer; and for use in combination with Abraxane for the treatment of metastatic triple-negative breast cancer.
Development History and FDA Approval Process for Tecentriq
|Mar 18, 2019|| FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer|
|Mar 8, 2019|| FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer|
|Dec 6, 2018|| FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer|
|Apr 17, 2017|| FDA Grants Genentech’s Tecentriq (atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer|
|Oct 18, 2016|| FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer|
|May 18, 2016|| FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma|
|Apr 10, 2016||FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer|
|Mar 14, 2016||FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority Review for Advanced Bladder Cancer|
|Jan 8, 2016||Roche Presents Updated Results for Investigational Cancer Immunotherapy Atezolizumab in Advanced Bladder Cancer|
|Aug 26, 2015||Syndax Enters Clinical Trial Collaboration In Cancer Immunotherapy Combining Entinostat and Atezolizumab|
|Aug 16, 2015||Pivotal Phase II Study Showed Atezolizumab Shrank Tumors in People with a Specific Type of Lung Cancer|
|Jul 12, 2015||In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.